Harris Feinstein
Psychiatry · Tampa, FLNPI 1396893624
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 143 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 13.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $882 and has fallen 59.9% since, to $354 in 2025.
Across 143 payments — averaging $25.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$502
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$431
- Alkermes, Inc.$359
- Johnson & Johnson$318
- Neos Therapeutics, LP$265
- Otsuka America Pharmaceutical, Inc.$257
- plus $2K from 11 others
What the payments were for
- Food & beverage$3,670100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $502 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $431 |
| Alkermes, Inc. | 12 | $359 |
| Johnson & Johnson | 32 | $318 |
| Neos Therapeutics, LP | 2 | $265 |
| Otsuka America Pharmaceutical, Inc. | 18 | $257 |
| Axsome Therapeutics, Inc. | 2 | $243 |
| Tris Pharma Inc | 2 | $229 |
| Sunovion Pharmaceuticals Inc. | 13 | $203 |
| Ironshore Pharmaceuticals Inc. | 5 | $184 |
| Neurocrine Biosciences, Inc. | 10 | $142 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| E.r. Squibb & Sons, L.L.C. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 5 | $106 |
| Indivior Inc. | 6 | $81 |
| Teva Pharmaceuticals USA, Inc. | 3 | $50 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $50 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$373
- Adzenys XR-ODT$265
- QUVIVIQ$125
- Dyanavel XR$125
- COBENFY$125
- SUNOSI$122
- Auvelity$121
- VRAYLAR$118
- Onyda XR$104
How this compares
$3,670 in reported general payments places this provider in the 80th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Thiothixene | 11 | $977 |
| Divalproex Sodium | 12 | $276 |
| Bupropion Hcl SrBupropion Hcl | 11 | $202 |
| Risperidone | 12 | $190 |
| Sertraline Hcl | 20 | $88 |
| Alprazolam | 30 | $68 |
| Olanzapine | 12 | $52 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Tampa
- David SheehanTampa$631K
- Jamie FernandezTampa$418K
- Hardeep SinghTampa$374K
- Kenneth PagesTampa$274K
- Chetan GandhyTampa$94K
- Deborah Knudson GonzalezTampa$81K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
- Todd BroderSt Augustine$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.